Ex-PRESS device exposure warning

Article

With increasing numbers of patients undergoing filtration surgery with the Ex-PRESS Miniature Glaucoma devices (Optonol), anterior segment surgeons should be aware of the potential for device exposure.

With increasing numbers of patients undergoing filtration surgery with the Ex-PRESS Miniature Glaucoma devices (Optonol), anterior segment surgeons should be aware of the potential for device exposure, according to a case series reported in the December 2007 issue of the Journal of Glaucoma.

Joshua Stein and colleagues from Duke University, North Carolina, USA conducted a retrospective chart review to identify all patients who were referred for Ex-PRESS miniature glaucoma device exposure between January 2004 and December 2005.

A total of six patients (eight eyes) experienced device exposure, with an average time to exposure of 8.5 months. In two eyes, the shunt had been inserted under a half-thickness flap. In both these eyes and in one additional eye, Mitomycin-C had been used during shunt insertion. In five eyes, visual acuity worsened after the device was removed and all eight patients required concomitant glaucoma surgery with device removal.

The authors of this report suggest that anterior segment surgeons should be aware of the possibility of device exposure when using the Ex-PRESS.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.